Let's talk medical research

Clinical trials are an integral part of the medical industry, as they are required for any new treatment to be approved. Every medicine used today, whether prescription or over the counter, is a result of the rigorous research process that is a clinical trial — and for these trials to take place, volunteers are vital.

Recruiting patients for a clinical trial can be a challenging process. Studies show that many patients report having little or no knowledge of clinical trials, and sponsors and researchers often report having difficulties finding and enrolling patients in studies. However, once patients understand more about the medical research process, many individuals do want to participate in a clinical trial.

Clinical trials are how researchers advance their knowledge about potential new treatments, including medications, medical devices, and lifestyle interventions. Clinical trials are divided into phases, each with a distinct duration, purpose, and number of volunteers needed. Before any new treatment becomes available on the market, it must go through this process, as required by the FDA.

Connecting patients with clinical research opportunities is our mission here at Antidote, but often, we find that misconceptions can serve as barriers to achieving this goal. It’s important to carefully weigh the pros and cons of participating in a clinical trial but to do this effectively, it’s critical to have accurate information.

Antidote’s podcast, Talk of the Towne, hosted by Antidote’s Senior Clinical Informatics Manager, Dr. Richard Towne, is an interview series featuring members of Antidote's partner network. During each episode, Rich and his guests take a closer look at particular therapeutic areas, the latest research developments, and specific pain points that impact the patient population.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that results in weakened breathing and reduced lung function. In the U.S., it is estimated that 50,000 individuals are diagnosed with IPF each year, and 140,000 are estimated to live with the disease in America.

We are excited to announce that we have received the Silver Award from EcoVadis for the second year in a row. EcoVadis is the world’s largest, most trusted provider of business sustainability ratings, with a global network of more than 90,000 companies. Antidote was evaluated within this network to receive this award, and scored in the top 25% of companies focusing on Corporate and Social ...

In the third quarter of 2018, we conducted a survey with SCORR Marketing to learn more about the patient perception of clinical trial participation. This extensive survey involved nearly 4,000 patients from our patient advocacy group partners and provided valuable insights into the demographics of these individuals, their motivations for engaging in research, and what matters most to them ...

Alzheimer’s disease, the most prevalent type of dementia, is diagnosed in more than 6 million Americans. Estimates project that by 2050, 13 million individuals will be diagnosed with Alzheimer’s disease. This condition ranks among the top 10 causes of death in the United States, profoundly impacting those diagnosed, their loved ones, and their caregivers. Currently, Alzheimer’s remains a disease ...

Globally, there are thousands of research studies and clinical trials conducted each year, all with the shared goal of bringing new treatment options and medical devices to the market. However, approximately 80% of clinical trials are delayed or closed because of problems with recruitment.